Asha Das, MD has more than 10 years of drug development experience in the pharmaceutical industry. Most recently she held positions of increasing responsibility at Genentech, including leading activities related to the approval and launch of Avastin® in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to PD-L1.
Prior to Genentech, Dr. Das was an associate director at Eisai, focused on clinical activities related to the oncology therapeutics HALAVEN® and LENVIMATM. Previously, she was head of the neuro-oncology program at Cedars-Sinai in Los Angeles. Dr. Das is certified in neurology by the American Board of Psychiatry and Neurology and in the sub-specialty of neuro-oncology and was a clinical fellow in neuro-oncology at Massachusetts General Hospital. She completed a residency in neurology at Cornell Medical Center. Dr. Das also held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore. She obtained her medical degree and bachelor’s degree from Cornell University.